Today: 7 February 2026
Subscribe

Amgen stock dips as Lumakras combo trial ends; MariTide data now the next watch

Amgen stock dips as Lumakras combo trial ends; MariTide data now the next watch

NEW YORK, December 30, 2025, 2:56 PM ET — Regular session Amgen Inc. shares were down 0.4% at $328.32 at 2:56 p.m. ET on Tuesday, after trading between $325.90 and $330.18. The modest move matters because investors are grading Amgen’s pipeline for new growth while several mature products face price pressure and biosimilar competition. Oncology and obesity remain two key swing factors for the stock heading into 2026. Biotech stocks lagged, with the iShares Nasdaq Biotechnology ETF down about 1.1%, while the healthcare sector ETF was roughly flat and the S&P 500 ETF hovered near unchanged. Verastem Oncology said it
30 December 2025
·····
Texas Instruments stock today: TXN flat after ReRAM licensing deal as Fed minutes land

Texas Instruments stock today: TXN flat after ReRAM licensing deal as Fed minutes land

NEW YORK, December 30, 2025, 14:44 ET — Regular session Texas Instruments Incorporated (TXN) shares were little changed on Tuesday after memory developer Weebit Nano said it had licensed its resistive random access memory, or ReRAM, technology to the chipmaker. The stock was down about 0.01% at $175.67 in afternoon trade, and TI executive Amichai Ron said the partnership would give customers access to “industry-leading NVM technology.” Weebit The announcement matters because embedded non-volatile memory — storage that keeps data when power is off — is a key building block for chips that run cars, factory equipment and other electronics
30 December 2025
······
Mastercard stock dips in thin year-end trade as Fed minutes sharpen rate focus

Mastercard stock dips in thin year-end trade as Fed minutes sharpen rate focus

NEW YORK, December 30, 2025, 14:45 ET — Regular session Mastercard Incorporated shares were down 0.3% at $576.37 in afternoon trading on Tuesday, after moving between $574.55 and $579.49 earlier in the session. Volume was about 683,000 shares. The small move still matters into year-end because investors use card networks as a bellwether for consumer spending. Mastercard earns fees when transactions run across its network, so shifts in shopping and travel can show up quickly in volume trends. Rates are also front and center for the group. Payment processors trade like high-quality growth stocks inside financials, which can make them
30 December 2025
·····
Arcutis Biotherapeutics stock slides today as biotech pulls back, ARQT down nearly 3%

Arcutis Biotherapeutics stock slides today as biotech pulls back, ARQT down nearly 3%

NEW YORK, December 30, 2025, 14:45 ET — Regular session Arcutis Biotherapeutics shares fell 2.9% to $27.74 in afternoon trading on Tuesday, after moving between $27.72 and $28.65. Volume was about 0.6 million shares. The drop outpaced broader biotech gauges, with the SPDR S&P Biotech ETF down about 1.5% and the iShares Nasdaq Biotechnology ETF off about 1.1%. That matters for Arcutis because it trades as a growth story tied to one product franchise, leaving the stock prone to outsized moves when sentiment sours across biotech and high-multiple names. Arcutis is a commercial-stage medical dermatology company whose main product, Zoryve
30 December 2025
·····
Accenture stock slips as Argus cuts target; Fed minutes keep Wall Street cautious

Accenture stock slips as Argus cuts target; Fed minutes keep Wall Street cautious

NEW YORK, December 30, 2025, 14:33 ET — Regular session Accenture plc shares were down about 0.5% on Tuesday, drifting lower in a quiet year-end session after Argus lowered its price target on the IT services company while maintaining a buy rating. The move matters because Accenture is widely treated as a read-through on corporate technology spending, and late-December liquidity is thin. In that backdrop, even routine changes in analyst targets can move large-cap consulting names more than usual. Traders were also navigating a fresh macro signal after Federal Reserve meeting minutes showed policymakers split over how quickly to keep
30 December 2025
·····
Vera Therapeutics stock drops 3% today as biotech slips into year-end trading

Vera Therapeutics stock drops 3% today as biotech slips into year-end trading

NEW YORK, December 30, 2025, 2:26 PM ET — Regular session Vera Therapeutics, Inc. shares slid 3.4% to $50.45 in afternoon trading on Tuesday, giving back some recent gains as biotech stocks softened late in the year. The move matters now because Vera has become a bellwether “event-driven” biotech name, where day-to-day trading can swing sharply as investors calibrate risk around FDA timelines and competitive positioning in kidney disease. Thin year-end liquidity can amplify those swings, and traders have been quick to trim exposure to smaller, higher-beta healthcare names when the sector loses momentum. Minutes from the Federal Reserve’s December
30 December 2025
······
Rigetti stock today: RGTI steadies as Fed minutes and year-end flows keep quantum names jumpy

Rigetti stock today: RGTI steadies as Fed minutes and year-end flows keep quantum names jumpy

NEW YORK, December 30, 2025, 14:34 ET — Regular session Rigetti Computing shares edged up 0.3% to $22.34 on Tuesday afternoon, after swinging about 3% between the day’s high and low. IonQ rose 1.2% and D-Wave Quantum gained 1.6%. The muted move matters because quantum-computing stocks have become a high-beta pocket of the market, prone to sudden swings when liquidity thins and rate expectations shift. With the calendar turning, traders are re-pricing how much room the Federal Reserve has to ease in 2026. U.S. stocks were subdued in holiday-thin trading, with investors rotating within technology after a late-year run-up, Reuters
30 December 2025
·······
Ares Management stock drops 3% in New York as Fed minutes hit year-end trading

Ares Management stock drops 3% in New York as Fed minutes hit year-end trading

NEW YORK, December 30, 2025, 2:20 PM ET — Regular session Shares of Ares Management Corp fell 3.1% to $163.85 in afternoon trading on Tuesday, down $5.20 from Monday’s close. The stock traded between $168.99 and $163.49, with about 966,000 shares changing hands. The move matters because Ares is closely tied to credit-market conditions. Investors are weighing where interest rates settle in early 2026 and what that means for fundraising, deal activity and returns in private credit. A Reuters Breakingviews column said private credit is losing some of its pricing edge as bank-led bond and loan markets regain momentum, pushing
30 December 2025
····
AT&T stock today ticks higher as Fed minutes loom and year-end rotation lifts telecoms

AT&T stock today ticks higher as Fed minutes loom and year-end rotation lifts telecoms

NEW YORK, December 30, 2025, 14:35 ET — Regular session AT&T Inc shares were up 0.1% at $24.80 in afternoon trade on Tuesday, hovering near the top of a tight day range as the broader market struggled for direction. The stock traded between $24.75 and $24.85. The move matters because income-heavy telecom stocks often trade with interest-rate expectations at year-end, when many investors rebalance portfolios. The yield on the 10-year U.S. Treasury note rose 1.8 basis points — a basis point is 0.01 percentage point — to 4.134%, and traders were awaiting the Federal Reserve’s meeting minutes later in the
30 December 2025
·········
PayPal stock slips in late trade after Fed minutes; here’s what PYPL investors are watching next

PayPal stock slips in late trade after Fed minutes; here’s what PYPL investors are watching next

NEW YORK, December 30, 2025, 14:33 ET — Regular session PayPal Holdings (PYPL.O) shares were down about 0.6% at $59.14 in afternoon trading on Tuesday, after the Federal Reserve’s latest meeting minutes sharpened the debate over where interest rates go next. The move matters because liquidity is thin into year-end, when smaller trades can have an outsized impact on price. For consumer-facing fintech names like PayPal, rate expectations and spending signals can quickly swing sentiment. Investors are also recalibrating for 2026 after fresh color from the Fed on how comfortable policymakers are with further easing. The minutes are a detailed
30 December 2025
····
Soleno Therapeutics stock slides today: SLNO drops on investor-alert headline as biotech sector slips

Soleno Therapeutics stock slides today: SLNO drops on investor-alert headline as biotech sector slips

NEW YORK, December 30, 2025, 2:16 PM ET — Regular session Shares of Soleno Therapeutics, Inc. fell 3.1% to $46.09 in afternoon trading on Tuesday, after a law firm said it was investigating potential claims on behalf of investors. The drop outpaced declines in biotech benchmarks, with the SPDR S&P Biotech ETF down about 1.4% and the iShares Nasdaq Biotechnology ETF off about 1.1%. The move matters because Soleno is still in the early innings of commercializing its first marketed drug, and the stock has traded with sharp swings as investors debate demand, safety perception and pricing power. Legal headlines
30 December 2025
···
Spotify stock dips today as Fed minutes loom and investors parse its 2025 feature push

Spotify stock dips today as Fed minutes loom and investors parse its 2025 feature push

NEW YORK, December 30, 2025, 14:32 ET — Regular session Spotify Technology S.A. (NYSE: SPOT) shares were down about 0.6% at $577.84 in afternoon trading on Tuesday, after swinging between $576.69 and $584.52. The stock’s drift came as the S&P 500 and Nasdaq were subdued in choppy, year-end trading, with investors awaiting the Fed’s December meeting minutes later in the day. “It’s just a healthy rebalancing of allocations more so than an emotionally driven sell-off,” said Mark Hackett, chief market strategist at Nationwide. Reuters For Spotify, the timing matters because the market’s appetite for growth stocks often moves with interest-rate
30 December 2025
····
1 … 1,082 1,083 1,084 1,085 1,086 … 2,711

Stock Market Today

Vodafone shares steady up after Q3 wobble — Germany, buyback and next results now set the tone

Vodafone shares steady up after Q3 wobble — Germany, buyback and next results now set the tone

7 February 2026
Vodafone shares rose 1.47% to 110.60p Friday, recovering part of Thursday’s 4.68% drop after a Q3 update. Group revenue climbed 6.5% to €10.5 billion, but Germany’s 0.7% service revenue growth missed some forecasts. Vodafone launched a new €500 million buyback tranche, bringing total buybacks since May to €3.5 billion. Investors remain focused on Germany’s pace and cash flow execution.
NatWest Group stock: buyback filing and Rightmove mortgage deal set up a busy week

NatWest Group stock: buyback filing and Rightmove mortgage deal set up a busy week

7 February 2026
NatWest shares closed up 1.45% at 659.4 pence Friday, buoyed by a buyback of 797,428 shares and a new digital mortgage deal with Rightmove. The Bank of England held rates at 3.75% but signaled possible cuts, with markets pricing in two reductions for 2026. NatWest plans to expand its Accelerator community to 50,000 members by 2026. Annual results are due Feb. 13.
Unilever share price holds at 5,250p as results week looms — what investors watch next

Unilever share price holds at 5,250p as results week looms — what investors watch next

7 February 2026
Unilever shares closed flat at 5,250p in London Friday, underperforming the FTSE 100’s 0.6% gain. The company issued 4.2 million new shares for employee plans, bringing total shares to over 2.18 billion. Investors await Q4 and full-year results on Feb. 12, with analyst consensus pointing to 3.9% Q4 sales growth. Unilever’s U.S. ADR rose 0.8% to $72.12.
BP share price near 52-week high ahead of Feb 10 earnings as buyback runs on

BP share price near 52-week high ahead of Feb 10 earnings as buyback runs on

7 February 2026
BP shares closed up 1.9% at 478 pence Friday, just below a 52-week high, as the company continued buybacks ahead of next week’s results. BP repurchased 2.789 million shares on February 6. Oil prices firmed on geopolitical risk, with Brent at $68.05 a barrel, but sector outlook remains uncertain. Investors await BP’s earnings and dividend decision due Tuesday.
Go toTop